Objectives Clinical studies of chloroquine (CQ) and hydroxychloroquine (HCQ) in COVID-19
disease reported conflicting results. We sought to systematically evaluate the effect of CQ …

Background There is no effective therapy for COVID-19. Hydroxychloroquine (HCQ) and
chloroquine (CQ) have been used for its treatment but their safety and efficacy remain …

Many recent studies have investigated the role of either Chloroquine (CQ) or
Hydroxychloroquine (HCQ) alone or in combination with azithromycin (AZM) in the …

Abstract Background and Aims; To investigate the association between use of angiotensin-
converting enzyme inhibitor (ACEI)/angiotensin-receptor blocker (ARB) and outcomes of …

Much of routine cancer care has been disrupted due to the perceived susceptibility to SARS-
CoV-2 infection in cancer patients. Here, we systematically review the current evidence base …

Background The primary goal of the presented cross-sectional observational study was to
determine the clinical and demographic risk factors for adverse coronavirus disease 2019 …

Background Currently, the SARS-CoV-2 promptly spread across China and around the
world. However, there are controversies about whether preexisting chronic kidney disease …

Background The association of antihypertensive drugs with the risk and severity of COVID-
19 remains unknown. Methods and Results We systematically searched PubMed …

Currently severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) transmission has
been on the rise worldwide. Predicting outcome in COVID‐19 remains challenging, and the …

What is known and Objective Controversy has arisen in the scientific community on whether
the use of renin‐angiotensin system (RAS) inhibitors in the context of COVID‐19 would be …